NVIDIA Spotlights Digital Diagnostics as AI Healthcare Pioneer at GTC 2025

SAN JOSE, Calif., March 19, 2025 /PRNewswire/ -- Digital Diagnostics, a leader in autonomous AI-driven healthcare solutions, is honored to announce that its groundbreaking technology was highlighted by NVIDIA during CEO Jensen Huang's keynote address at the GPU Technology Conference (GTC) 2025. This recognition underscores Digital Diagnostics' commitment to transforming healthcare through innovative artificial intelligence.

GTC 2025, hosted by NVIDIA, is the world's premier AI conference, bringing together over 25,000 in-person attendees and 300,000 virtual participants to explore the latest advancements in AI and accelerated computing. Jensen Huang's keynote, delivered at the SAP Center in San Jose, focused on AI's transformative impact across various industries, including healthcare.

During the keynote video, Digital Diagnostics' AI platform was showcased, emphasizing its role in enhancing diagnostic accuracy and accessibility in medical imaging and improving outcomes for patients. During the CEO's keynote address, NVIDIA highlighted how "tokens can see disease before it takes hold" and specifically recognized Digital Diagnostics as a leader in autonomous AI diagnostics.

Digital Diagnostics' flagship product, LumineticsCore^® is the first FDA-cleared autonomous AI system designed to detect diabetic retinopathy, a leading cause of blindness. By integrating NVIDIA's advanced computing technologies, LumineticsCore™ delivers real time and reliable diagnostic results, empowering healthcare providers to make timely decisions and improve patient outcomes.

"We are deeply honored by this NVIDIA recognition," said John Bertrand, CEO of Digital Diagnostics. "Our mission has always been to combine cutting-edge AI with clinical excellence to enhance patient care. Leveraging NVIDIA's powerful technology has been instrumental in achieving this goal."

Digital Diagnostics continues to innovate in the field of autonomous AI, with ongoing research and development aimed at expanding its diagnostic capabilities to address a broader range of medical conditions.

About Digital Diagnostics

Digital Diagnostics Inc. is a pioneering AI diagnostics company on a mission to transform the quality, accessibility and affordability of global health care through the application of technology in the medical diagnosis and treatment process. The company, originally founded by Michael Abramoff, MD, PhD, a neuroscientist, practicing fellowship-trained retina specialist, and computer engineer, is led by him and co-founder John Bertrand.

Digital Diagnostics is paving the way for autonomous and assistive AI technology that is free of bias to become a new standard of care, contributing to democratizing health care and closing care gaps. The company works closely with patient advocacy groups, provider organizations, regulators, and other quality of care and ethics-focused stakeholders to enable the adoption of health care AI. For more information and the latest news follow: https://digitaldiagnostics.com/ 

SOURCE Digital Diagnostics